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Background: The risk of depression is high for cancer patients and a large portion of cancer 
patients are age 65 and over. Both depression and cancer are economically burdensome and 
depression is associated with healthcare expenditure increase for elderly patients. However, 
whether comorbid depression affects healthcare expenditures in elderly cancer patients from 
payers’ and patients’ perspectives is largely unknown. Objective: To investigate whether 
depression is associated with higher healthcare expenditure among elderly cancer patients 
from both payers’ and patients’ perspectives and, and determine whether depression is 
associated with higher probability of having high out-of-cost burden. Methods: From the 
Medicare Current Beneficiary Survey (MCBS)-Medicare database, we identified breast, lung 
and prostate cancer patients aged 65 years or older who were newly diagnosed between 2007 
and 2012 using Medicare claims. Presence of depression was based on self-reports from the 
surveys. Healthcare expenditures included expenditures incurred in the cancer diagnosis year 
and the subsequent calendar year. High out-of-cost burden was referred to as out-of-pocket 
cost as over 10% of respondent’s income. For the analyses of healthcare expenditures, 
generalized linear models (GLM) and two-part models were used to examine the impact of 
depression on healthcare expenditures when controlling for all other covariates assessed in 
 
 
 
the study. We stratified the analyses by healthcare service types and payers. For the analyses 
of high out-of-pocket cost burden, logistic regression was used to estimate whether 
depression was associated with higher probability of having high out-of-pocket cost burden. 
Results: Of the 710 elderly breast, lung and prostate cancer patients identified, 128 (18%) 
reported depression. The results revealed that elderly cancer patients with depression had 
$11,454 higher overall total healthcare expenditures. From Medicare’s perspective, elderly 
patients with depression incurred $8,280 higher expenditures, $4,327 higher medical 
provider expenditures and $870 higher expenditures on other services. They were also more 
likely to use inpatient services and other services. From the patients’ perspective, they had 
higher healthcare expenditures, medical provider expenditures and other expenditures 
($1,270, $654 and $465, respectively). For high out-of-pocket cost burden, although the 
unadjusted result was significant, the adjusted result was not. Conclusions: Elderly patients 
with depression had significantly higher healthcare expenditures from the payers’ 
perspective. Although they did not have higher out-of-pocket cost burden, they did have 
higher healthcare expenditures from patients’ perspectives and over different expenditure 
types. These findings provide compelling evidence for policy makers, physicians and 
researchers to develop guidelines for and conduct studies of depression screening, diagnosis 
and treatment for geriatric cancer populations.  
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BACKGROUND  
Statement of the Problem  
It has been shown that the risk of depression is higher for cancer patients than those 
with stroke, diabetes and heart disease.1, 2 Moreover, many studies have suggested that 
patients’ short-term and long-term physical and mental health are negatively impacted by the 
coexistence of cancer and depression. 3-5Therefore, understanding the mental health need 
among cancer patients is a vital task to improve holistic wellbeing for cancer patients. 
Additionally, as a result of the aging population in the United States and the high prevalence 
of cancer among the elderly, the majority of cancer survivors is 65 and over; it is projected 
that, by 2040, 73% of 26.1 million cancer survivors will be 65 years or older.6 Considering 
the serious negative impact of coexisting depression on cancer patients, it is important to 
study the association between cancer and depression among the elderly. 
This study focuses on three most prevalent cancers: breast cancer, lung cancer and 
prostate cancer. In particular, prostate cancer is the most prevalent among males, and breast 
cancer is the most prevalent among females. Lung cancer ranks the second in both males and 
females.7 The goal of the study is to understand the economic impact of depression on elderly 
cancer patients through these three important types of cancers. 
As one of the most economically burdensome disorders, depression is usually 
associated with excess healthcare expenditures. In particular, it has been shown that 
depression is associated with increase in direct health care costs for the elderly patients with 
depression. 8, 9However, the healthcare expenditures of depression, in addition to cancer 
 
 
2 
 
itself, from the perspective of both payers and patients is largely unknown for elderly cancer 
patients, which is a quite unsatisfactory situation. 
Therefore, it is vital to study the additional healthcare expenditure of depression 
among elderly depressed breast, prostate and lung cancer patients. 
 
Objectives 
The overall objective of this study is to estimate the additional healthcare 
expenditures of depression for elderly breast, prostate and lung cancer patients with 
depression from both the payer and patients’ perspectives. In addition, this study will 
examine how elderly depressed breast, prostate and lung cancer patients are adherent on 
antidepressant therapy and related factors. In particular, the aims of this study are: 
Aim 1. From payer’s perspective, determine if elderly breast, lung and prostate cancer 
patients with depression have more healthcare expenditures than those without depression 
• Hypothesis: elderly breast, lung and prostate cancer patients with depression will incur 
higher healthcare expenditures than those without depression in payer’s perspective 
Aim 2. From patients’ perspective, determine if elderly breast, lung and prostate 
cancer patients with depression have more out-of-pocket healthcare expenditures than those 
without depression 
• Hypothesis: elderly breast, lung and prostate cancer patients with depression will incur 
higher out-of-pocket healthcare expenditures than those without depression  
 
 
 
3 
 
Aim 3. Determine if elderly breast, lung and prostate cancer patients with depression 
are more likely to have high out-of-pocket cost burden than those without depression 
• Hypothesis: depression will be significantly associated with increased odds of high out-
of-pocket cost burden 
 
Public Health Significance 
There is a high prevalence of depression among elderly cancer patients. Considering 
the fact that cancer and depression is each associated with very high expenditures, it is 
important to study the healthcare expenditures when the two coexist, which is not clear from 
existing studies. The result of the Aims 1 and 2, by examining the overall health expenditures 
from both payer and patients’ perspectives will bridge this important gap in the literature. 
Additionally, the result will increase the awareness of depression issues for elderly cancer 
patients and help evaluate relevant depression prevention/management interventions for this 
population. Also, the expenditure estimates can be used in cost-effectiveness studies of 
interventions addressing depression for elderly cancer patients: the reduction of depression 
related healthcare costs would partially offset the intervention costs. The result of Aim 3, 
examining whether depression is associated with a high out-of-pocket cost burden, will 
strengthen the importance of studying individual financial burden for this population. 
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Literature Review 
High Proportion of Elderly Patients with Breast, Lung and Prostate Cancer  
It is estimated that 62% of the cancer survivors living in the U.S. are 65 years or older 
in 2016. By 2040, the proportion of elderly cancer survivors will grow to 73% and the 
absolute number will become close to 30 million.6 Like most cancers, breast, lung and 
prostate cancers are diseases of the elderly people. In the U.S., the median age of diagnosis is 
about 62 for female breast cancer, 68 for male breast cancer;10 70 for lung cancer and 66 for 
prostate cancer.10 Such high concentration of cancer among the elderly reinforces the 
importance of understanding how this disease affects the overall clinical and economic 
wellbeing of this population. This paper is specifically interested in exploring the intersection 
of cancer and depression among those 65 and older.  
High Prevalence of Depression among Breast, Prostate and Lung Cancer Patients  
Cancer often places significant psychological burdens on patients not only at the time 
of diagnosis but also during treatment and afterwards. Indeed, many studies show that cancer 
patients are more likely have depression.11-13 Furthermore, depression symptoms of cancer 
patients are frequently ignored by clinicians and viewed to be the normal psychological 
reactions of cancer diagnosis and treatments. It has been shown that detection rate of 
depression is low among cancer patients and the rate of depression is often underestimated. 
14, 15 For example, in a large study of over 1,100 cancer patients, physicians only correctly 
identified 33% of patients with mild to moderate depression, and only 13% of patients with 
severe depression were diagnosed.15 As a result, the actual rate of depression among cancer 
patients are likely to be higher than the reported numbers in existing studies. 
 
 
5 
 
Breast, prostate and lung cancers are all highly associated with depression and 
depression can appear at any time during the course of the cancers. For example, a study 
reported the prevalence of depression among breast cancer patients ranged from 1.4% to 
46%. 16 For lung cancer, it is also reported that about 11% to 44% of lung cancer patients 
suffered from depression.16 In a study estimating longitudinal changes in depression 
symptoms, 38% had depression symptoms at baseline and 14% more developed “new-onset 
depression symptoms” during treatment.17 For prostate cancer, “the lifetime prevalence of 
major depressive disorder in adults in the U.S.” is 17%. 18An article identified 50,147 elderly 
patients with newly diagnosed prostate cancer found that 8.54% of them were diagnosed with 
depression following their prostate cancer diagnosis. 19A meta-analysis identifying 27 journal 
articles and with a pooled sample size of 4,494 prostate patients identified pre-treatment, on-
treatment and post-treatment depression prevalence of 17.27%, 14.70% and 18.44%, 
respectively.20 
Negative Impact of Depression on Breast, Lung and Prostate Cancer Patients  
Depression has negative impact on many aspects of cancer patients’ outcomes.  For 
example, depression has been linked to higher mortality, poorer quality of life, and poorer 
treatment adherence for cancer patients in general. 3-5 
Similar negative impact of depression has been found on breast, lung and prostate 
cancer. For example, a study found that breast cancer patients with depression had lower 
overall quality of life. 21Additionally, depression reduces likelihood of breast cancer patients’ 
adherence to their medical treatments.21, 22 
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For lung cancer, it has been shown the depression affected the functional status 
negatively. 23Also, depression has been shown to decrease survival among patients recently 
diagnosed lung cancer.24 
For prostate cancer, depression also reduces treatment effectiveness, and lowers the 
survival.25  
High Healthcare Expenditures of Breast, Lung and Prostate Cancer and Depression  
Depression is one of the most economically burdensome disorders worldwide. 
Moreover, studies have suggested that the already excessive healthcare cost of depression has 
increased rapidly in recent years; the extra economic burden for patients with major 
depressive disorder had increased by 21.5% from 2005 to 2010 in the U.S..26, 27  
It is also well-known that cancer is a very expensive disease for both the patients and 
the society as a whole. For instance, a study projected that the cost of cancer in the US would 
reach $173 billion in 2020, representing a 40% increase from 2010. In 2010, the annualized 
mean net costs of female breast cancer care for elderly patients was $23,078 in initial phase, 
$2,207 in continuing phase, and $62,856 in last year of life for cancer death. The annualized 
mean net costs of female lung cancer care for elderly patients was $60,533 in initial phase, 
$8,130 in continuing phase, and $92,524 in last year of life for cancer death. For male lung 
cancer patients, the numbers were $60,885, $7,591 and $95,318, respectively, and for elderly 
prostate cancer patients, the numbers were $ 19,710, $3,201 and $ 62,242, respectively. The 
national cost of care for female breast cancer patients is $16.50 billion, which is the highest 
cost among all cancers. The national costs of care for lung cancer and prostate cancer, $12.12 
billion and $11.85 billion, respectively, which rank 4th and 5th among all cancers. It is 
 
 
7 
 
projected that the national costs in continuing phase for prostate and female breast cancers 
would rank the top in 2020.28 
Additionally, for breast cancer, a synthesis of published evidence in 2009 estimated 
the “lifetime per-patient costs” of breast cancer varied from $20,000 to $100,000.29Also, a 
study about the economic burden of lung cancer in 2005 estimated that the overall costs, 
from diagnosis to no more than two years after diagnosis, were about $46,000.30 Moreover, 
some research estimated lifetime costs for prostate cancer patients enrolled in Medicare at 
$110,520 in 2004 U.S. dollars, about 31% of which is prostate cancer-related.31 
Additional HealthCare Expenditures of Depression for Breast, Lung and Prostate Cancer 
Patients  
Although depression is associated with an increase in direct health care costs for 
elderly patients with depression8, 9, only a few studies have examined the healthcare 
expenditures of depression for cancer patients. In a recent paper about cancer patients aged 
21 years and older, a study showed that those with depression had more than 30% greater 
one-year healthcare expenditures compared with those without depression. They found 
depression increased many types of health care expenditures, including total, outpatient, and 
prescription expenditures; depression also increased their emergency service utilization.32 
In terms of elderly cancer patients, a paper about prostate cancer showed that among 
elderly prostate cancer patients, those with depression had significantly “higher inpatient 
pharmacy, physical therapy and laboratory costs in all phases”; additionally, they had higher 
medical and surgical supply costs, except for the terminal phase, compared with those 
without depression.19 
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Overall, the existing studies either did not examine the overall health care 
expenditures including both the payer’s and patients’ perspectives or did not focus on elderly 
cancer patients or did not examine multiple types of cancers as this study proposes to do. 
Hence, the healthcare expenditures of depression, in addition to cancer itself, from the 
perspective of both payers and patients is not studied well for elderly cancer patients. 
Conceptual Model 
This study utilized an expanded Andersen Behavioral Model as the conceptual 
framework.33 Concisely, the model is composed of five main constructs 1) predisposing 
factors; 2) enabling factors; 3) need factors; 4) personal health practices and use of health 
services; 5)  the external environment. As a result of the flexibility of the model, it can be 
easily to be applied to analyze the relationship between various patient characteristics, 
detection of depression as well as the healthcare expenditures associated with depression.  
Variable selection for this study (Figure 1) was guided by published studies34-36 that 
adopted the Anderson Behavioral Model while taking into consideration data elements 
available in Medicare Current Beneficiary Survey (MCBS)-Medicare. A valuable list of 
factors associated with health service utilization for adult cancer survivors are summarized in 
a recent review paper on Andersen Behavioral Model. 34Additionally, some studies employed 
this model to assess the relationship of different factors and healthcare expenditures35, 36. For 
example, a study using Medicaid data examined the “association between depression 
treatment and healthcare expenditures among adults with Type 2 Diabetes Mellitus and 
depression”, taking “coexisting chronic physical conditions” into account, used this model to 
select independent variables other than the main predictor: “gender, race and age” as 
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predisposing factors; “Medicaid eligibility status” as enabling factors; “ mental health 
conditions” as individual’s level of need; “healthcare-seeking behaviors  and total baseline 
healthcare expenditures” as personal health practices and use of health services; “state of 
residence, community level healthcare infrastructure and community level social 
determinants of health variables” as external environment35.  Another study using MCBS 
data examined the association between depression treatment and healthcare expenditure also 
used this model as the conceptual framework to select variables other than the main 
predictor: “gender, race and age” as predisposing factors; “marital status, education, poverty 
status, and prescription drug coverage” as enabling factors; “perceived health status and 
functional status” as individual’s level of need; “smoking status, body mass index (BMI), 
depression treatment, and the baseline year log-transformed health expenditures” as personal 
health practices and use of health services; “metro status” as external environment36.  
Figure 1: List of Covariates included in the analyses  
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•Depression StatusMain predictor
•Age
•Race/Ethnicity
•Gender
Predisposing 
Factors
•Poverty status
•Supplemental Insurance Type
•Marital status
•Educational Attainment
Enabling Factors
•Perceived health status 
•Comorbidities
•Functional Health Status
•Cancer Types
Need Factors
•Body mass index (BMI)
•Smoking Status
Personal health 
practices and 
use of health 
services
•Urban/rural status
External 
Environment
 
Outcomes 
 Aim 1 & 2: Additional healthcare 
expenditures of depression from 
both payers’ and patients’ 
perspectives 
 Aim 3: High out of pocket cost 
burden 
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METHODS 
Data Source 
The 2007-2013 Medicare Current Beneficiary Survey (MCBS)-Medicare data 
sponsored by the Centres for Medicare & Medicaid Services (CMS) was used. The data was 
generated by sampling a nationally representative sample of non-institutionalized Medicare 
beneficiaries, who are surveyed continuously. The data set had two types of files: Access to 
Care (MCBS/AC) and Cost and Use (MCBS/CU). MCBS/CU files linking Medicare claims 
to survey-reported events were used. The data set contained comprehensive and detailed 
information on patient demographics, socioeconomic status, access to healthcare, healthcare 
utilization, and self-reported health status and symptoms, and is linked to the Medicare 
claims to the survey.37  
Study Design 
This was a retrospective cohort study examining Medicare Current Beneficiary 
Survey (MCBS) respondents (age>=65) diagnosed with breast, lung or prostate cancer 
between January 2007 and December 2012.The study captured depression status based on 
self-reports from survey data no later than subsequent follow-up calendar year after cancer 
diagnosis and collected their expenditures information between January 2007 and December 
2013. 
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Analyses  
For Aim1 & 2: Determine if elderly breast, lung and prostate cancer patients with 
depression have more healthcare expenditures than those without depression from payer’s 
and patients’ perspective, respectively.  
First, patient characteristics and healthcare expenditures were compared by patients’ 
depression status, using the Chi-square tests for categorical variables and t-test for 
continuous variables. 
Then, this study applied multivariate analysis that included the depression status as one 
of the covariates. The presence of depression was defined by two questions in the survey: (1). 
were you depressed the last 12 months? (2). did you lose interest the last 12 months? A patient 
was considered to have depression if he/she responded positively to both of the questions.  
Since healthcare expenditures were highly skewed, the logarithmic transformation with 
ordinary least squares (log OLS) regression (ln(𝑌𝑌𝑖𝑖) = 𝑋𝑋𝑖𝑖𝛽𝛽 + 𝜀𝜀𝑖𝑖.) and a general linear model 
(GLM)(𝑙𝑙𝑙𝑙 𝐸𝐸(𝑦𝑦𝑖𝑖|𝑥𝑥𝑖𝑖) = 𝑥𝑥𝑖𝑖𝛽𝛽) were considered. Compared to log OLS model, GLM has 
advantages in the ways that it avoids needing the smearing estimator for retransforming model 
estimates of the difference in mean expenditures, and avoids retransformation bias of log OLS 
models, so GLM was chosen. 
            Then, Park test (Diagnostics for variance functions) was used to select one of the GLM 
models. The variance functions is below: 
𝑣𝑣𝑣𝑣𝑣𝑣(𝑦𝑦𝑖𝑖|𝑥𝑥𝑖𝑖) = 𝛼𝛼[𝐸𝐸(𝑦𝑦𝑖𝑖|𝑥𝑥𝑖𝑖)]λ  
Because λ = 2 in our study, so gamma model was used.38  
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The change in healthcare expenditures associated with depression were calculated as 
the difference between the exponentiation of the sum of the intercept and the parameter 
estimate for depression and exponentiation of the intercept. The percent change in healthcare 
expenditures associated with depression was calculated as exponentiation of the parameter 
estimate for depression minus one (eβ − 1). 
When stratifying the analyses by healthcare service types, there were a large number 
of zeros for some of the expenditure categories such as inpatient and other health services 
categories of Medicare healthcare expenditures. To deal with this issue, two-part models, 
logistic models estimated in the first part and GLMs with gamma distribution and log link in 
the second part, were also used to estimate adjusted healthcare expenditures.  
This study detected multicollinearity issue by computing variance inflation factor (VIF) 
to quantify how much the variance is inflated. 
           All statistical analyses were adjusted for the MCBS complex survey design and 
performed by using survey sampling and analysis procedures in SAS Enterprise Guide version 
6.1 (e.g., surveyfreq, surveymeans) (SAS Institute Inc, Cary, NC and Stata 14.2(e.g., svy glm) 
(StataCorp, College Station, TX)  
For Aim 3: Determine if elderly breast, lung and prostate cancer patients with 
depression are more likely to have high out-of-pocket cost burden than those without 
depression 
This study used multivariate logistic regression to estimate significant predictors to 
high out-of-pocket cost burden. The equation is below. 
𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙[𝜋𝜋(𝑥𝑥)] = 𝛽𝛽0 + 𝛽𝛽1𝑥𝑥1 + 𝛽𝛽2𝑥𝑥2 + 𝛽𝛽3𝑥𝑥3 … + 𝛽𝛽𝑖𝑖𝑥𝑥𝑖𝑖 
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First, patient characteristics were analyzed by patients’ depression status, using the 
Chi-square tests. The high out-of-pocket cost burden rate was also compared by depression 
status, according to the independent variables of the five factors of the expanded Anderson 
Behaviour Model. 
Then, this study included all independent variables in the multivariate logistic 
regression regardless of the univariate logistic regression results, because these variables are 
based on theories and empirical evidence. For independent categorical variables, the reference 
group year of cancer diagnosis (2007–2009), gender (male), age in years at diagnosis (65–74) 
and race/ethnicity (Non-Hispanic white),marital status (married), educational attainment (less 
than high school), poverty status measured as income (inflated to constant 2017 dollars, 
adjusting for annual consumer price index for medical care services 39) to percentage of the 
federal poverty level (less than 200%),supplemental insurance coverage type (private 
insurance with drug coverage)40,cancer site (lung), perceived health status (excellent/very 
good/good), functional status limitations(the number of activities of daily living (ADLs) with 
limitations [none limitation]),the number of comorbid health conditions(none or 1 condition). 
(current), BMI (underweight or normal),41 and metro status (metropolitan).  
This study tested for multicollinearity by computing variance inflation factor (VIF) to 
quantify how much the variance is inflated.  
All statistical analyses were adjusted for the MCBS complex survey design and 
performed by using survey sampling and analysis procedures in SAS Enterprise Guide version 
6.1 (e.g., surveyfreq, surveymeans) (SAS Institute Inc, Cary, NC and Stata 14.2(e.g., svy glm) 
(StataCorp, College Station, TX)Measurement/Measures 
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In terms of cohort creation, three types of cancer and depression were the key 
variables. For depression, the study will define the patient as having depression symptoms 
via two questions in the survey: (1). were you depressed the last 12 months? (2). did you lose 
interest the last 12 months? A patient was considered to have depression if he/she responded 
positively to both of the questions. The combination of these two questions was found to 
have 91% sensitivity and 86% specificity in detecting depression in cancer and palliative care 
and hence is a good measure of depression presence based on patient self-report.42 The three 
types of diagnosed cancers were defined by ICD-9-CM code in Medicare Claims data: breast 
cancer (174.x), lung cancer (162.x), and prostate cancer (185.x). The “newly diagnosed” 
cases were identified by using a 12-month wash-out period. 
Outcome measures and independent variables by specific aims 
Aim 1. From payer’s perspective, determine if elderly breast, lung and prostate 
cancer patients with depression have more healthcare expenditures than those without 
depression 
In this aim, the outcome variable was Medicare payments, which was described in 
Table 1. Medicare payments included all healthcare services, including inpatient, skilled 
nursing facility, hospital outpatient, home health, hospice, prescription drugs, and medical 
provider. Payments were measured over the cancer diagnosis year as well as the subsequent 
calendar year. The independent variables included depression status and the five factors the 
expanded Anderson Behaviour Model, which were controlled for in the analysis and 
described in Table 2. 
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Aim 2. From patients’ perspective, determine if elderly breast, lung and prostate 
cancer patients with depression have more out-of-pocket healthcare expenditures than those 
without depression 
In this aim, the outcome variable was out-of-pocket (OOP) expenditures and 
described in Table 1. OOP expenditures included all personal expenditures for both Medicare 
covered and non-covered healthcare services, including inpatient, skilled nursing facility, 
outpatient, medical providers, prescription drugs, home health, hospice and dental services. 
OOP expenditures were measured over the cancer diagnosis year and the subsequent calendar 
year. The independent variable included depression status and the five factors in expanded 
Anderson Behaviour Model, which were controlled in the analysis and described in Table 2. 
The components of healthcare expenditures for Aim 1 and Aim 2 are defined in the 
following way: Inpatient expenditures are payments for care received for inpatient hospital 
events (admissions). Skilled nursing facility are payments for care received for short-term 
facility stays. Hospital outpatient expenditures are the payments for services received in 
outpatient settings. An outpatient setting means “outpatient department or outpatient clinic of 
a hospital”. Inpatient, skilled nursing facility and hospital outpatient expenditures are 
payments for the facility costs only.  The provider payments would be included in medical 
provider expenditures- the payments for services received from medical providers, unless the 
medical providers were actually employed by the facility. Medical providers include 
practitioners “such as chiropractors, podiatrists, audiologists and optometrists; mental health 
professionals such as psychiatrists, psychologists and clinical social workers; therapists such 
as physical therapists, speech therapists, occupational therapists, and intravenous and 
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respiratory therapists; other medical practitioners such as nurses and paramedics; and other 
places offering medical care, such as clinics, neighborhood health centers, infirmaries and 
urgent care centers.” Home health and hospice expenditures are payments for services 
received from health professionals in home health and hospice settings. The health 
professionals include “nurses, doctors, social workers, therapists and hospice workers”. 
Prescribed medicine expenditures are expenses for all prescription medications “except those 
provided by the doctor or practitioner as samples and those provided in an inpatient setting.” 
Dental expenditures are the payments for dental services.43 
Aim 3. Determine if elderly breast, lung and prostate cancer patients with depression 
are more likely to have high out-of-pocket cost burden than those without depression 
In this aim, the outcome variable was high out-of-pocket cost burden and described in 
Table 1. High out-of-pocket cost burden was referred to as out-of-pocket cost as over 10% of 
respondent’s income.40, 44  The income question is “what is you and your spouse’s total 
income?”, so the income value was divided by two if a respondent reports income for both 
himself/herself and the spouse.  
The main predictor was depression status. Other potential determinants of high out-
of-pocket cost burden included the five factors in expanded Anderson Behaviour Model, 
which were controlled in the analysis and described in Table 2. 
 
Table 1: Outcome measures 
Aim Measures Definition Measurement 
Aim 1 Healthcare 
expenditures of 
payer’s 
perspective 
Medicare 
payments 
Continuous 
variable:2017 
Dollars 
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Aim 2  Healthcare 
expenditures of 
patients’ 
perspective 
Patients’ self-
report out-of-
pocket 
expenditures 
Continuous 
variable:2017 
Dollars 
Aim 3 High out of 
pocket cost 
burden 
Patients’ out-of-
pocket cost is 
over 10% of the 
personal 
income40, 44 
Categorical 
Variable: Yes or 
No 
 
Table 2: Independent Variables  
Independent 
Variables 
Definitions Measurement 
Main Predictor 
Depression Status Patients’ depression 
status 
Categorical Variable: Yes 
or No 
Predisposing characteristics 
Age Group Patients’ age group at 
cancer diagnosis 
Categorical Variable: 65-
74 years old, 75+ years 
old 
Race/ethnicity Patients’ 
race/ethnicity 
Categorical Variable: 
Non-Hispanic White, , 
other 
Gender Patients’ gender Categorical Variable: 
Male, Female 
Enabling Factors 
Poverty Status  income (inflated to 
constant 2017 dollars, 
adjusting for annual 
consumer price index 
for medical care 
services39 ) to federal 
poverty level 
Categorical variable: less 
than 200%, greater than or 
equal to 200% 
Supplemental 
insurance  
Patients’ 
supplemental 
insurance 
Categorical Variable: 
Private insurance with 
drug coverage; public with 
drug coverage; Medical 
insurance only; drug 
insurance only; None  
Marital status Patients’ marital 
status at cancer 
diagnosis 
Categorical Variable: 
Other(Single/separated/div
orced), Married  
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Educational 
Attainment 
Patients’ educational 
attainment 
Categorical Variable: Less 
than High School; High 
School graduate; Greater 
than High School 
Need Factors 
Number of 
comorbid health 
conditions 
Patients comorbid 
chronic conditions, 
including heart 
disease, stroke/brain 
hemorrhage, 
hypertension, diabetes 
mellitus, arthritis, 
mental disorder other 
than depression, 
neurological 
conditions, and lung 
disease  
Categorical Variable: 
 None or one condition; 
more than one condition 
Cancer Type Cancer type Categorical Variable: 
Breast, Lung, Prostate 
Perceived health 
status  
Patients’ perceived 
health status 
Categorical Variables: fair 
or poor, good, very good 
or excellent 
Functional Health 
Status Limitations 
Patients’ number of 
activities of daily 
living (ADLs) with 
limitations 
Categorical Variables: 
none, at least one 
limitation 
Personal health practices and use of health services 
Smoking Status Patients’ smoking 
status 
Categorical Variable: 
Current, Past, Never 
Body mass index 
(BMI) 
Patients’ BMI Categorical Variable: 
under-weight or normal,  
overweight, obese 
External Environment 
Metro status Indicator of whether 
patients living in 
metropolitan 
Categorical Variable: 
metropolitan, non-
metropolitan 
 
Study Cohort 
This study considered all Medicare Current Beneficiary Survey (MCBS) respondents 
(age>=65) between January 2007 and December 2012; and collected their expenditures 
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information between January 2007 and December 2013.The participants in the cohort were 
elderly breast, lung and prostate cancer patients (age>=65 years).  
The inclusion/exclusion criteria: 
Inclusion criteria: 
• Respondents newly diagnosed with cancer(breast, lung or prostate) using a one-year 
wash-out period and at least 65 years old at the diagnosis between January 2007 and 
December 2012 
• Respondents with continuous enrollment in Medicare Part A and Part B 
• Respondents enrolled in Medicare at least 1 year before cancer diagnosis 
• Respondents having “at least 1 inpatient or 2 outpatient or medical provider claims with 
a qualifying cancer diagnosis”40 
• Respondents’ outpatient or provider claims have to be at least 30 days apart 
 
Exclusion criteria: 
• Respondents with Medicare Advantage Plans 
• Respondents with missing social-demographic information 
• Respondents who resided in long-term care facilities 
• Respondents who were lost follow up during the study period 
Sample Size Calculation  
To calculate the sample size, a generally accepted power of 0.80, and an alpha level 
of 0.05 were used.  For Aims 1 and 2, multiple regression sample size calculation in PASS 
1545 was used. Other parameters including a total of 22 controlled variables, one tested 
independent variable,  the squared multiple correlation coefficient assumed by the null 
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hypothesis(𝛽𝛽02), squared multiple correlation coefficient where 0.8 power is calculated(𝛽𝛽12),  
were entered into the sample size calculation for multiple regression in PASS 1545.  This 
study set 𝛽𝛽02 to 0. Based on the study results, the coefficient of depression status was 0.3, thus 
0.09 was used for 𝛽𝛽12. The result indicated that 106 observations would be sufficient. This 
study actually had 710 observations, which is beyond the sample size calculation result; so 
the sample size is not a concern here.  
For Aim 3, logistic regression sample size calculation in PASS 1545 was used. Other 
parameters including the baseline probability at the study population mean(𝑃𝑃0), odds ratio , 
one categorical independent variable of interest, percent of N (the percent of sample with 
depression in this study),R-Squared of independent variable of interest with other controlled 
variables(𝑅𝑅2) were entered into the sample size calculation for logistic regression in PASS 
1545.  Based on the study results, 𝑃𝑃0 was 0.4, odds ratio was 1.8, N was 20% and 𝑅𝑅2 was 
0.08. The result indicated that 692 observations would be sufficient. This study actually had 
710 observations, which is more than the sample size calculation result; so the study has 
sufficient sample size here.  
Data Collection 
For identifying study cohort, this study used data from the Cost and Use files of MCBS-
Medicare for years 2007 through 2012. This study captured cancer diagnosis using claims and 
depression presence using survey part. For healthcare expenditures collection, this study used 
data from the Cost and Use files of MCBS-Medicare for years 2007 through 2013. For Aim1, 
it examined healthcare expenditures in the year of diagnosis and subsequent calendar year 
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using claims. For Aims 2 and 3, it examined out-of-pocket expenditures in the year of diagnosis 
and subsequent calendar year using surveys.  
 
Data Management 
The de-identified datasets were stored on the secure server in University of Texas 
MD Anderson Cancer Center and the data was stored on a secured and encrypted format. The 
desktop was protected by strong security systems in University of Texas MD Anderson 
Cancer Center. 
All statistical analyses were conducted in SAS Enterprise Guide 6.1 (SAS Institute, 
Cary NC) and/or Stata version 14 (Stata Corporation, College Station, TX). This study was 
reviewed by the Institutional Review Board (IRB) at University of Texas School of Public 
Health to ensure appropriate study design and data management. 
 
Human Subjects, Animal Subjects, or Safety Considerations  
The MCBS Data is a de-identified data. Hence, this research qualifies for minimal risk. 
 
 
Summary and Implications 
There were some limitations associated with the data and study design. First, MCBS 
data was not linked to cancer registry data, so this used medical claims to identify different 
cancer types, which might cause potential misclassification. Second, some information such 
as out of pocket payments were based on self-report, which might be subject to recall bias. 
However, MCBS data has been considered as a principle resource for assessing out of pocket 
cost for Medicare beneficiaries, which is a reliable resource for this study.40 Moreover, 
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MCBS has taken some measures to minimize the recall bias: for example, the respondents 
are requested to take their facilitating records of all their healthcare events to the interviews. 
Third, this study was an observational retrospective cohort study, which may have 
unmeasured confounding factors than cannot be controlled for.  
In terms of implications, the study evaluated the additional health care expenditures 
of depression in both payer and patients’ perspective and estimate the high out-of-pocket 
burden among elderly cancer patients. The key findings of this study, not previously 
documented in other studies of elderly Medicare beneficiaries with cancer and depression, 
will allow us to better understand the impact of depression on elderly cancer patients. By 
estimating the additional healthcare expenditures associated with depression for elderly 
cancer patients and identifying the population with cancer and depression who are at risk of 
high out-of-pocket cost burden, this study will not only promote the awareness of the 
psychological needs of elderly cancer patients among all stakeholders, such as policy makers, 
clinicians, patients and their families, but also further the progress of targeted interventions to 
improve depression management and evaluations of depression-relevant interventions for this 
population. 
 
Timeline 
Task Month in 2018 
1 2 3 4 5 6 7 8 9 10 11 12 
Proposal Writing and Defense             
IRB Approved             
Data Clean and Merge             
Data Analysis             
Dissertation Writing             
Dissertation Defense             
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JOURNAL ARTICLE – 1 
Association between depression and healthcare expenditures among elderly cancer 
patients 
 
Introduction 
Studies have shown that the risk of depression is higher for cancer patients than for those with 
stroke, diabetes and heart disease.1, 2 While the reported prevalence of depression among 
cancer patients has varied by study design and definitions of depression, a previous meta-
analysis reported a pooled mean prevalence ranging from 8% to 24%.3 Moreover, cancer 
patients’ short-term and long-term physical and mental health are negatively impacted by 
depression comorbidity, as depression has been linked to higher mortality, poorer quality of 
life, and poorer treatment adherence for cancer patients in general.4-6 Additionally, as a result 
of the aging population in the United States and high prevalence of cancer among the elderly, 
a large portion of cancer patients are 65 and over; it is projected that by 2040 approximately 
70% of those diagnosed with cancer will be 65 years or older.7 Therefore, addressing the 
mental health needs of elderly cancer patients is vital to improve the wellbeing of both this 
population and society as a whole. 
In addition to being one of the most economically burdensome disorders overall, depression is 
usually associated with excess healthcare expenditures. In particular, it has been shown that 
depression is associated with increased direct healthcare costs for elderly patients with 
depression. 8, 9 However, only a few studies have examined the healthcare expenditures of 
depression for cancer patients.  
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One paper focusing on the nonelderly military population showed that military healthcare 
beneficiaries with both cancer and depression had significantly higher annual healthcare costs 
compared with those who only had cancer ($16,212 vs $7,728). Moreover, patients with cancer 
and depression also had more inpatient, outpatient and medication services utilization.10 A 
recent paper about adult cancer patients aged older than 21 years, showed that compared with 
those without depression, those with depression had about 32% greater one-year total 
healthcare expenditures including all third-party payments and out-of-pocket expenditures by 
patient or family. In particular, depression increased many types of healthcare expenditures, 
such as total, outpatient, and prescription expenditures for cancer patients. But this paper did 
not stratify the analyses by payers.11 A more recent paper from the University of California 
San Diego Healthcare System, examining healthcare charges for cancer patients in the first 
year after diagnosis, found that depressed individuals had 113% higher total annual healthcare 
charges compared to those without depression.12 
In terms of the impact of depression on elderly cancer patients’ healthcare expenditure, a study 
examining the association of depression with increased healthcare costs among prostate cancer 
patients, showed that those with depression had about 30% higher costs compared with those 
without depression from Medicare’s perspective during the year after cancer diagnosis.13 Also, 
patients with depression had more hospitalization, outpatient and emergency services 
utilization.  
Limitations of existing studies include failure to examine overall healthcare expenditures 
stratified by payers’ and patients’ perspectives, or failure to focus on elderly cancer patients; 
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most did not examine multiple cancer types. Hence, the healthcare expenditure associated with 
depression in the context of multiple cancer types from the perspective of both payers and 
patients is not well studied for elderly cancer patients. 
Methods 
 
Conceptual framework 
This study utilized an expanded Andersen Behavioral Model as the conceptual framework.14 
The model is composed of five main constructs: 1) predisposing factors, which include gender, 
race/ethnicity, age at diagnosis and year of cancer diagnosis; 2) enabling factors, which include 
supplemental insurance type, marital status, educational attainment and poverty status; 3) need 
factors, which include number of comorbidities, cancer site, perceived health status and 
functional status; 4) personal health practices and use of health services, which include 
smoking status and body mass index (BMI); and 5) external environment, measured as metro 
status in this study. 
Study design 
This is a retrospective cohort study that examined the healthcare expenditures associated with 
depression for elderly cancer patients. In this study, we identified cancer diagnosis based on 
Medicare claims between January 2007 and December 2012; captured depression status based 
on self-reports from survey data either in the year of cancer diagnosis or the subsequent 
calendar year; and measured healthcare expenditures in the year of diagnosis and subsequent 
calendar year after cancer diagnosis.  
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Data source 
This study used 2007-2013 Cost and Use files of Medicare Current Beneficiary Survey 
(MCBS)-Medicare sponsored by the Centers for Medicare & Medicaid Services (CMS). 
MCBS-Medicare is generated by sampling a nationally representative sample of Medicare 
beneficiaries, who are surveyed up to three rounds per year for four successive years. The data 
set contains two types of files that are released annually: Access to Care (MCBS/AC) and Cost 
and Use (MCBS/CU). The MCBS/CU files were used because they link Medicare claims to 
survey-reported events. Therefore, the data contains “complete expenditure and source of 
payment data on all healthcare services,” even if the services are not covered by Medicare. 
Additionally, the data set contains comprehensive and detailed information on patient 
demographics, socioeconomic status, healthcare utilization, and self-reported health status and 
symptoms.15  
Ascertainment of study cohort 
The algorithm to identify cancer patients was based on clinical diagnoses in claims. The 
beneficiaries were considered to be diagnosed with cancer based on the International 
Classification of Diseases, Ninth Revision, Clinical Modification (ICD‐9‐CM) (140-172, 174-
208, 225, 227.3 and 227.4) and were required to have at least one inpatient or two outpatient 
claims or medical provider claims with a cancer diagnosis based on the ICD-9-CM codes. The 
service date between the two outpatient claims was required to be at least 30 days. 
Additionally, all patients included in the analytical sample had to be continuously enrolled in 
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Medicare Parts A and B without Medicare Advantage enrollment and not reside in a long‐term 
care facility during the study period so as to ensure the completeness of Medicare claims and 
prescribed medicine event (PME) files. Patients who were lost to follow-up during the study 
period were excluded. Newly diagnosed cases were identified by using a 12-month wash-out 
period. 
If clinical diagnosis codes indicated more than one cancer site, this study applied a hierarchical 
process to assign beneficiaries to the cancer site that is more likely to have been the primary 
tumor location. For instance, a patient with diagnosis codes for both lung and brain cancer 
would be assigned to the lung cancer group. 16, 17  Lastly, this study only included beneficiaries 
belonging to groups of breast, lung and prostate cancer sites with ICD-9-CM codes as 174.x, 
162.x, and 185.x, respectively. 
Identification of depression 
This study defined the patient as having depressive symptoms via two questions in the survey: 
(1). “In the last 12 months, how much of the time did you feel sad, blue or depressed? “(2). “In 
the last 12 months, have you had 2 weeks or more when you lost interest or pleasure in the 
things that you usually cared about or enjoyed?” A patient was considered to have depression 
if he/she responded “all of the time” or “most of the time” to the first question, and/or answered 
“yes” to the second question.18, 19 The combination of these two questions was found to have 
91% sensitivity and 86% specificity in detecting depression in cancer and palliative care and 
hence is a good measure of the presence of depression based on patient self-report.20 
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Dependent variables 
The dependent variables included total healthcare expenditure, healthcare expenditure by 
service types, and payer types. The total healthcare expenditures were combined by MCBS 
from all payers’ payments and respondents’ out-of-pocket (OOP) payments, and include 
payments for different services types, including prescribed medicines, dental, home health, 
hospice, hospital inpatient, skilled nursing facility, medical provider, and hospital outpatient. 
In addition to total healthcare, we also analyzed subtypes of expenditures by healthcare 
services and payers. The healthcare services included inpatient (hospital inpatient and skilled 
nursing facility), hospital outpatient, medical providers, prescribed medicines, and other (i.e., 
home health, dental, and hospice). The payers included Medicare, other third-parties (i.e., other 
public [Medicaid, Veterans Affairs Health Insurance], individually purchased insurance, 
employer-sponsored insurance, and other payments) and patients’ OOP expenditures. The 
expenditures were inflated to constant 2017 dollars, adjusting for annual consumer price index 
for medical care services.21  
The measurement period for expenditures included the year of diagnosis and subsequent 
follow-up calendar year after cancer diagnosis. While it would have been ideal to measure 
expenditures in the 12 months following cancer diagnosis, some expenditures include service 
types and payers that are only reported on an annual basis, such as dental services, OOP costs 
and other third-party payers. 
Other independent variables  
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Besides depression status, the other independent variables belonging to the five constructs in 
the expanded Andersen Behavioral Model were also identified by self-reports from the survey 
data. Predisposing characteristics were: year of cancer diagnosis (2007–2009; 2010–2012), 
gender (female; male), age in years at diagnosis (65–74; 75 and over) and race/ethnicity (Non-
Hispanic white; other). Enabling characteristics included marital status (married; other), 
educational attainment (less than high school; high school; greater than high school), poverty 
status measured as income inflated to constant 2017 dollars, adjusting for annual consumer 
price index for medical care services 21 and converted to percentage of the federal poverty level 
(less than 200%; greater than or equal to 200%) and supplemental insurance coverage type 
(private insurance with drug coverage; public with drug coverage; medical insurance only; 
drug insurance only; none)17. Need characteristics included: cancer site (breast; lung; prostate), 
perceived health status (excellent/very good/good; fair/poor), functional status limitations(the 
number of activities of daily living (ADLs) with limitations [none limitation; ≥1 limitation]) 
and the number of comorbid health conditions, including heart disease, stroke/brain 
hemorrhage, hypertension, diabetes mellitus, arthritis, mental disorder other than depression, 
neurological conditions, and lung disease (none or 1 condition;>1 condition). Personal health 
practices and use of health services included smoking status (current; past; never), BMI 
(underweight or normal, defined as BMI <25 kg/m2; overweight, defined as BMI ≥25- 29.9 
kg/m2; obese/morbid obese, defined as BMI ≥ 30 kg/ m2).22 External environment was 
captured by metro status (metropolitan; non-metropolitan).  
Statistical analyses 
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The chi-square test for categorical variables and t-test for continuous variables were used to 
analyze patient characteristics and healthcare expenditures by patients’ depression status; the 
tests were weighted using cross-sectional sampling weights.23 To estimate different types of 
adjusted additional expenditures associated with depression, generalized linear model (GLM) 
regressions with gamma distribution and log link, determined by modified park test24, were 
used. This approach has an advantage compared to log-cost regression (log OLS model) in the 
way that it evaluates transformation of the difference in mean cost, and avoids retransformation 
bias of log OLS models24. In the regression analysis, depression status and all other 
independent variables were included.  
In the analysis of healthcare expenditure by service types and payer types, we observed a large 
number of zeros for some of the expenditure categories such as inpatient and other health 
services categories of total healthcare expenditures.  When the proportion of zero expenditures 
was non-negligible, we adopted two-part models 24 with multivariable logistic regressions in 
the first part and GLMs with gamma distribution and log link in the second part. The first part 
modeled the probability of utilizing certain services, and adjusted odds ratios (AOR) and 95% 
confidence intervals (CIs) were provided. The second part estimated the adjusted effect of 
depression among those who had non-zero expenditures. 
All statistical analyses were accounted for the MCBS complex survey design and were 
performed by using survey sampling and analysis procedures (e.g., surveyfreq, surveymeans)  
in SAS Enterprise Guide version 6.1 (SAS Institute Inc, Cary, NC) and Stata 14.2 (e.g., svy 
glm) (StataCorp, College Station, TX).  
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Results 
The sample included 710 elderly beneficiaries who were newly diagnosed with breast, lung 
and prostate cancer, among which 128 (17.7%) had depression. The description of the study 
sample by depression status is provided in Table 1. Statistically significant differences were 
found with respect to supplemental insurance, perceived health status, functional status, and 
number of comorbid health conditions. Specifically, patients with both public insurance and 
drug coverage were more likely to report depression (35.8%) compared with those with both 
private insurance and drug coverage (16.9%), medical insurance only (13.9%) and other 
supplemental insurance (18.1%). More patients perceiving fair/poor health status reported 
depression (32.7%) compared with those perceiving excellent/very good/good health (13.6%). 
Additionally, patients with at least one functional status limitation were more likely to report 
depression (35.7%) compared to those with no limitations (15.1%); and those with more than 
one comorbid health condition were more likely to report depression (20.9%) compared with 
those with none or one comorbid condition (11.1%). 
In Table 2, unadjusted total healthcare expenditures were compared between the patients with 
depression and those without, presented as total overall expenditures and stratified by service 
types and payers. For the categories of expenditures containing zeros, the comparison were 
also performed among the patients with non-zero expenditures. Overall, the total healthcare 
expenditure was significantly higher for patients with depression ($70,918 vs $44,106). In 
analyses stratified by healthcare service types, patients with depression spent significantly 
more in medical provider services ($25,052 vs $16,068). Regarding users of other services, 
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those with depression also spent significantly more ($8,653 vs $3,559). In analysis stratified 
by payers, patients with depression had significantly more Medicare payments ($48,875 vs 
$28,856). Additionally, Medicare and OOP expenditures — representing the most important 
payer and patient perspectives, respectively — were compared between the two groups by 
service types. In sub-service type analyses for Medicare healthcare expenditures, patients with 
depression had significantly more medical provider expenditures ($15,566 vs $10,832) and 
other services expenditures in beneficiaries who used these services ($12,218 vs $7,077). In 
sub-service type analyses for OOP healthcare expenditures, patients with depression had 
significantly more medical provider expenditures ($3,028 vs $1,903). 
Tables 3-5 provides results from adjusted regressions controlling for all the independent 
variables described in the methods section. Table 3 presents the adjusted total healthcare 
expenditures and percent change associated with depression from GLM and two-part models, 
overall and stratified by service types and payers. The results showed that significant 
differences were found in total healthcare expenditures and also in some total expenditure 
categories. Patients with depression had $11,454 higher total healthcare expenditures, which 
corresponded to 34.5% greater total healthcare expenditures. Among different service types, 
patients with depression had 45.9% higher medical provider expenditures and were 
significantly more likely to have inpatient services (AOR, 2.94; 95% CI, 1.82–4.74) compared 
with those without depression. In users of other services, patients with depression had 50.1% 
greater other services expenditure. In terms of payers, patients with depression not only 
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incurred $8,280(43.8%) more expenditures from Medicare’s perspective, but also 
$1,270(32.9%) higher expenditures from patients’ perspective.  
Adjusted Medicare healthcare expenditures and percent change associated with depression 
from GLM and two-part models stratified by service types are presented in Table 4. From 
Medicare’s perspective, among different healthcare services, patients with depression had 36% 
higher medical provider healthcare expenditures. Patients with depression were highly 
significantly more likely to use inpatient services (AOR, 2.7; 95% CI, 1.59–4.58) and other 
services (AOR, 2.55; 95% CI, 1.59–4.09). For patients who used other services, depression 
was associated with 47.2% greater other services expenditure.  
Table 5 displays the adjusted OOP healthcare expenditures and percent change associated with 
depression from GLM and two-part models stratified by healthcare service types. From the 
patients’ perspective, patients with depression had 47.1% and 53% higher medical provider 
and other healthcare expenditures, respectively. No significant results were found in inpatient 
and other services, which is possibly because of the small sample size.  
Discussion 
The current study used MCBS data, a nationally representative survey of Medicare 
beneficiaries, to estimate the incremental expenditures associated with depression for elderly 
breast, lung and prostate cancer patients. In this sample, the depression rate was 18% (19% for 
breast, 19% for lung and 16% for prostate). These rates fall in the range of 8% to 24%, which 
was estimated from a meta-analysis of depression prevalence among cancer patients assessed 
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by diagnostic interviews and self‐report instruments.3 The prevalence rate of 18% in this study 
is higher than a previous paper (14%) by Pan et al.11 This is plausible because the previous 
paper used International Classification of Diseases, Ninth Revision, Clinical Modification 
(ICD-9-CM) codes to capture clinical diagnosis of depression, while this study used a self-
report instrument. It has been shown that the detection rate of depression is low among cancer 
patients and depression is often underdiagnosed because their depression symptoms are 
frequently ignored by clinicians and viewed to be a normal psychological reaction of cancer 
diagnosis and treatment.25, 26 For example, in a large study of over 1,100 cancer patients, 
physicians only correctly identified 33% of patients with mild to moderate depression, and 
only 13% of patients with severe depression were diagnosed.26Also, a recent paper found that 
depression prevalence was highest by self-reported symptoms scales, followed by diagnostic 
interviews and ICD-9-CM codes based on claims databases.27 Depression rates vary broadly 
by cancer type and patient age; our study focused on the elderly while previous papers included 
adults of all ages and did not distinguish cancer types. 
Since the prevalence of self-reported depression is high for elderly cancer patients in this study, 
and depression is often unrecognized, it is essential to improve depression screening and 
diagnosis for this population. While some instruments such as the Geriatric Depression Scale 
(GDS)28 are commonly used to identify depression in the elderly, few studies have assessed 
their accuracy in the geriatric cancer setting. Considering the complexity and difficulty to 
identify and detect depression for geriatric cancer populations 29, more research is needed to 
find or develop accurate, appropriate and validated depression measurement tools.  
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Our study found that depression was associated with 34.5% greater adjusted total healthcare 
expenditures, which is consistent with a prior study using 2006-2009 Medical Expenditure 
Panel Survey data on cancer patients older than 21 years, where the percent increase associated 
with depression in total expenditures was about 30%.11 In terms of service subtypes of total 
healthcare expenditures, depression was associated with greater adjusted medical provider and 
other services expenditures (45.9 % and 50.1%, respectively). Also, depression was associated 
with higher likelihood of inpatient services use (AOR=2.94). These findings confirm that 
depression is correlated with excess healthcare expenditure and utilization for elderly cancer 
patients, and the higher expenditures are concentrated on certain services.  
When stratified by payers, depression was associated with 43.8% greater adjusted Medicare 
healthcare expenditures, which is higher than a previous paper (about 30%) about elderly 
prostate cancer patients from the Medicare perspective 13. The lower rate identified in that 
study may be explained by methodology, as the researchers only focused on prostate cancer 
while the current study included two more cancer types, which may have more influence on 
the expenditures. When diving deeper into the subtypes, significant findings were found in 
medical provider, inpatient and other services, suggesting that, as with total healthcare 
expenditures, the excess is mainly attributable to certain services.  
From the patients’ perspective, depression was associated with 32.9% higher OOP 
expenditures. The OOP expenditures did not include premiums since premiums are separated 
from actual spending.17. When expenditures on different service types were analyzed, 
significant findings were found for medical provider and other services. These findings stress 
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that the excess financial burden of depression is not only placed on the healthcare system but 
also on the patients themselves, indicating that comorbid depression can aggravate the personal 
financial burden that cancer patients already face. 
Subtype analyses from three aspects (i.e., total [all payers], Medicare and OOP expenditures) 
all highlighted higher expenditures in the category of medical provider services for elderly 
cancer patients with depression. In terms of total and Medicare analyses, depression was 
associated with increased inpatient services use. These results are consistent with previous 
studies irrespective of cancer diagnosis. For example, two studies of cancer patients using 
military and Medicare populations demonstrated that cancer patients with depression had more 
hospitalizations.10, 13 Also, depression is associated with increased risk of hospitalization in 
patients with heart failure. 30 
It is noteworthy that the estimated expenditures from our study can also contribute to the 
evaluations of depression-relevant interventions for this population, because the estimates can 
be applied in cost-effectiveness studies of interventions addressing depression for elderly 
cancer patients: the reduction of depression related healthcare cost would partially offset the 
intervention costs. 
Since cancer patients with depression incurred substantially higher healthcare utilization and 
expenditures from payers’ and patients’ perspectives than their counterparts without 
depression, it is possible that managing and treating depression effectively in cancer patients 
could improve health outcomes and potentially reduce healthcare expenditures. While 
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depression treatment may contribute to higher short-term expenditures (e.g., psychotherapy, 
psychotropic medications); expenditures could decrease in the long term. Currently, very few 
studies have examined whether depression treatment has an impact on reducing expenditures 
in the long-term. One study demonstrated that depression treatment (antidepressants, 
psychotherapy and both) increased healthcare expenditures for elderly breast, colorectal and 
prostate cancer patients from Medicare’s perspective in the short term but had no effect on 
long-term expenditures, however, the study’s follow-up period of two years after depression 
diagnosis may not have been long enough31. Encouragingly, studies about patients with other 
co-occurring chronic conditions and depression have shown positive results in reducing costs 
with depression treatment. For instance, a study about patients with comorbid conditions and 
type 2 diabetes mellitus along with depression showed that depression treatment 
(antidepressants, psychotherapy and both) decreased healthcare expenditures significantly 
during 12 month period after depression diagnosis.32 Another study focusing on patients with 
depression and diabetes showed reduced trends for 5-year mean total medical expenditures 
when comparing depression collaborative care and usual care.33 Future research needs to 
examine whether depression treatment in elderly cancer patients can lower healthcare 
expenditures, especially in the long run, from payers’ and patients’ perspectives; the depression 
treatment modalities best suited for this often vulnerable population need to be elucidated.  
This study has many strengths. It makes a significant contribution to the existing literature by 
estimating the healthcare expenditures associated with depression in the elderly cancer 
population from payers’ and patients’ perspectives. Also, by examining multiple expenditure 
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categories, our results detail where the excess economic burden of depression originated from 
in our study cohort. Additionally, because MCBS data links survey to Medicare fee-for-service 
claims, this study adjusted for a comprehensive list of independent variables, including patient-
level health factors that are generally not available in claims data, such as functional status, 
general health status and personal health practices. Moreover, this study captured complete 
healthcare expenditures including both Medicare and non-Medicare expenditures.  
There are some limitations associated with the data and study design. Firstly, some information 
such as OOP payments are based on self-report, which may be subject to recall bias. However, 
MCBS data is an established principle source for assessing OOP cost for Medicare 
beneficiaries, which is a reliable resource for this study.17 Moreover, MCBS includes measures 
to minimize recall bias: for example, the respondents are requested to take their facilitating 
records of all their healthcare events to the interviews. Secondly, this study is an observational 
retrospective cohort study, so the results cannot imply causation. Additionally, this study may 
have unmeasured confounding factors that cannot be controlled for. These unmeasured 
confounding factors may include cancer severity such as stage at diagnosis, which is not 
available in MCBS data. Although depression can happen during any stage of cancer, but many 
studies showed a higher prevalence of depression with advanced stage cancer.34, 35 Also, some 
studies showed that cancer costs were higher for cancer patients whose stage at diagnosis were 
more advanced.36 So the additional healthcare expenditures of depression may be 
underestimated. 
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Thirdly, the study sample was restricted to fee-for-service Medicare beneficiaries and the 
results may not be generalizable to other Medicare beneficiaries.  
This study has many important and unprecedented implications. To our best knowledge, it is 
the first study to provide a national estimate of depression prevalence in elderly patients with 
breast, lung, and prostate cancer, which are the three most common cancer types in the US, 
and the excess healthcare cost and utilization burden associated with depression for this 
population. This study adds to our understanding of the notable economic burden imposed by 
depression on cancer patients. Additionally, our findings reveal the psychological needs of 
many elderly cancer patients and their associated higher expenditures; the data may stimulate 
interest among many stakeholders including policy makers, clinicians, patients and their 
families. Also, the findings highlight the importance of effective depression screening, 
diagnosis, treatment and management. In terms of screening and diagnosis, specific 
screening/diagnostic criteria need to be implemented with standardized instruments validated 
in elderly cancer patients with depression. In terms of depression treatment and management, 
more research is needed to investigate whether treating depression has an impact on cost-
reduction over a longer period for both the healthcare system and patients, and to verify the 
efficacy of different depression treatments. Additionally, as recommended by other studies, 37-
39 integrated collaborative care treatment models need to be emphasized in the near future to 
monitor and treat depression in cancer patients.  
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Conclusions 
In this sample of elderly breast, lung and prostate cancer patients, patients with depression 
incurred significantly higher healthcare expenditures from payers’ and patients’ perspectives 
and across different expenditure types. These findings provide compelling evidence for policy 
makers and clinicians to improve depression screening, diagnosis and treatment in geriatric 
oncology. 
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Table 1.Characteristics of elderly cancer patients by depression status 
 
 
Without 
Depression 
With Depression 
Characteristics N Wt% N Wt % 
Total 582 82.3 128 17.7 
Predisposing 
Year of cancer diagnosis     
2007-2009 317 83.9 63 16.1 
2010-2012 265 80.7 65 19.3 
Gender     
Female 234 79.5 56 20.5 
Male 348 84.2 72 15.8 
Age     
65-74 177 79.4 48 20.6 
75 and over 405 84 80 16 
Race/ethnicity     
Non-Hispanic white 520 82.9 112 17.1 
Other 62 76.8 16 23.2 
Enabling 
Marital status     
Married 349 82.8 75 17.2 
Other 233 81.2 53 18.8 
Educational attainment     
Less than high school 114 77.9 34 22.1 
High school 213 85.3 39 14.7 
Greater than high school 255 81.8 55 18.2 
Poverty status     
LT 200% FPL 435 84.8 79 15.2 
GE 200% FPL 147 74.8 47 25.2 
Supplemental insurance**     
Private insurance with Rx 237 83.1 51 16.9 
Public insurance with Rx 53 64.2 27 35.8 
Medical Insurance only 259 86.1 42 13.9 
Other 33 81.9 8 18.1 
Need 
Cancer site     
Breast 208 80.8 44 19.2 
Lung 67 80.6 19 19.4 
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Prostate 307 83.7 64 16.3 
Perceived health status***     
Excellent/very good/Good 475 86.4 75 13.6 
Fair/poor 107 67.3 53 32.7 
Functional status 
limitation***     
None 426 84.9 78 15.1 
≥1 156 64.3 50 35.7 
Number of comorbid health 
conditions**     
None or 1 195 88.9 28 11.1 
>1 387 79.1 100 20.9 
Personal health practices and use of health services 
Smoking Status     
Current 38 77.9 11 22.1 
Past 319 79.9 76 20.1 
Never 225 86.6 41 13.4 
BMI     
Underweight/normal 206 80.4 54 19.6 
Overweight 258 83.7 49 16.3 
Obese/morbid obese 118 82.5 25 17.5 
External Environment 
Metro status     
Metropolitan 414 82.5 87 17.5 
Non-Metropolitan 168 81.5 41 18.5 
 
 ***P < .001, **.001 ≤ P < .01, *.01 ≤ P < .05 
Note: Wt%, Weighted percentage; LT, less than; GE, greater than or equal to; FPL, federal 
poverty level; Rx, prescription coverage; BMI, body mass index. 
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Table 2. Unadjusted healthcare expenditures by depression status 
 Full sample In users 
 
Without 
Depression 
(N=582) 
With 
Depression 
(N=128) 
Without Depression With Depression 
Healthcare Expenditures Mean(SE) $ Mean(SE) $ N(%) Mean(SE)$ N(%) Mean(SE)$ 
Total healthcare expenditures 
Overall*** 44106(2116) 70918(5759)     
By service types       
Medical provider*** 16068(934) 25052(2609)     
Hospital outpatient 8050(658) 8006(865)     
Prescribed medicine 7891(485) 10188(1242)     
     Inpatient*** 9424(925) 21184(2817) 206(35%) 28743(1890) 77(60%) 35712(3785) 
     Other*† 2658(237) 6488(1613) 430(74%) 3559(286) 97(76%) 8653(2152) 
By payers       
Medicare*** 28856(1716) 48875(4150)     
Out-of-
pocket(patient) 6511(291) 9442(1516) 
    
Other third-party 
payers 7950(402) 11722(2053) 
 
559(96%) 
 
8232(407) 
 
124(97%) 
 
12031(2099) 
Medicare healthcare expenditures 
By service types       
    Medical Provider** 10832(700) 15566(1545)     
    Hospital outpatient 5766(501) 5949(673)     
Inpatient** 8134(842) 17874(2608) 198(34%) 25658(1850) 75(59%) 31072(4458) 
Prescribed medicine 3000(375) 5258(1108) 299(51%) 5868(624) 69(54%) 9659(1969) 
Other**†† 1124(189) 4228(750) 103(18%) 7077(932) 48(38%) 12218(1652) 
Out-of-pocket healthcare expenditures 
By service types       
Medical provider** 1903(122) 3028(348)     
Prescribed medicine 1639(98) 1667(189)     
Other 2067(158) 4020(1316)     
Inpatient 391(117) 320(87) 74(13%) 3290(911) 27(21%) 1685(441) 
Hospital outpatient 499(77) 408(113) 359(62%) 823(112) 80(63%) 659(191) 
***P < .001, **.001 ≤ P < .01, *.01 ≤ P < .05, indicating significant difference between those 
with and without depression among th3 full sample. 
†††P < .001, ††.001 ≤ P < .01, †.01 ≤ P < .05, indicating significant difference between those 
with and without depression among patients with non-zero expenditures. 
Note: SE, Standard Error 
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Table 3. Adjusted effect of depression on total healthcare expenditures, overall and 
stratified by service types and payers  
 
AOR[95% CI] Coefficient 
(SE)  
$ 
Change % Change 
Overall  0.30(0.09)** 11454 34.5 
By service types     
Medical provider  0.38(0.1)*** 8213 45.9 
Hospital outpatient  -0.79(0.14) -617 -7.6 
Prescribed medicine  -0.07(0.11) -217 -6.5 
Inpatient‡ 2.94[1.82,4.74]*** 0.05(0.11) 1061 5.3 
Other‡ 1.05[0.65,1.69] 0.41(0.16)* 405 50.1 
By Payers     
    Medicare  0.37(0.1)*** 8280 43.8 
Out-of-pocket(patient)  0.28(0.13)* 1270 32.9 
Other  0.23(0.15) 2613 26.1 
 
***P < .001, **.001 ≤ P < .01, *.01 ≤ P < .05 
‡ Because a large number of patients did not have expenditures in these categories of 
expenditures, two-part models, with logistic regressions in the first part and GLMs with 
gamma distribution and log link in the second part were used to estimate the adjusted 
effect of depression.  
Note: SE, Standard Error 
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Table 4. Adjusted effect of depression on Medicare healthcare expenditures, stratified 
by service types 
 
AOR[95% CI] Coefficient(S
E)  $ Change % Change 
Medical provider  0.31(0.1)* 4327 36 
Hospital outpatient  -0.02(0.14) -97 -2.1 
Inpatient‡ 2.7[1.59,4.58]*** 0.05(0.12) 922 4.8 
Prescribed medicine‡ 0.88[0.53,1.46] -0.07(0.17) -76 -6.7 
Other‡ 2.55[1.59,4.09]* 0.39(0.17)* 870 47.2 
***P < .001, **.001 ≤ P < .01, *.01 ≤ P < .05 
‡ Because a large number of patients did not have expenditures in these categories of 
expenditures, two-part models, with logistic regressions in the first part and GLMs with 
gamma distribution and log link in the second part were used to estimate the adjusted 
effect of depression.  
Note: SE, Standard Error 
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Table 5. Adjusted effect of depression on out-of-pocket healthcare expenditures, 
stratified by service types  
 AOR [95% CI] Depression(SE)  $ Change % Change 
Medical provider  0.39(0.16)* 654 47.1 
Prescribed medicine  -0.02(0.1) -10 -2.3 
Other  0.43(0.2)* 465 53 
Inpatient‡ 1.71[0.97,3.01] -0.54(0.35) -1025 -41.8 
Hospital outpatient‡ 1.05[0.58,1.92] -0.26(0.22) -342 -23 
***P < .001, **.001 ≤ P < .01, *.01 ≤ P < .05 
‡ Because a large number of patients did not have expenditures in these categories of 
expenditures, two-part models, with logistic regressions in the first part and GLMs with 
gamma distribution and log link in the second part were used to estimate the adjusted 
effect of depression.  
Note: SE, Standard Error 
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TECHNICAL REPORT OF PROPOSED AIM 3 
Depression and high out-of-pocket cost burden among elderly cancer patients 
Results 
      In table 1, the rates of high-out-of-pocket cost burden were compared by depression 
status in total and according to predisposing, enabling, need, personal health practices and 
use of health services and the external environment factors. Overall, the depressed group was 
significantly more likely to have high out-of-pocket cost burden (53% vs 38.12%, p=0.023) 
compared to the non-depressed group. When stratified by other covariates, the depressed 
group was more likely to have high out-of-pocket cost burden in the groups of males, aged 
75 and over years old, other race/ethnicity, other married status, high school, public 
insurance with drug, prostate cancer, fair/poor health status, more than one comorbid health 
condition, never smokers, underweight/normal and metropolitan. 
     Table 2 presented the unadjusted effect of depression. The unadjusted effect was 
significant with an odds ratio of 1.83 (95% confidence interval: 1.08-3.09, 
p=0.024).Compared to the non-depressed group, the odds of having high out-of-pocket cost 
burden in the depressed group was 1.83 times that in the non-depressed group. 
    Table 3 presents the adjusted effect of depression. When controlling for the other 
independent variables, the effect became not significant-the adjusted odds ratio was 1.54 and 
the 95% confidence interval was 0.86-2.74(p=0.144).  
Discussion 
     In the sample of 710 elderly breast, lung and prostate cancer patients, 128 (18%) reported 
depression. In the depressed group 53% had high out-of-pocket cost burden while in the non-
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depressed group 38% had. When estimating the relationship between depression and high 
out-of-pocket cost burden, the unadjusted effect was significant while the adjusted effect was 
not significant and the odds ratio became smaller, from 1.83 to 1.54. 
      There might be some possible explanations. One possible explanation is that some 
covariates were confounders, which were correlated with both depression and high-out-of-
pocket cost burden and deflated the true estimate of the relationship. As confounding is a 
major threat to internal validity, in the absence of randomization, we used the multivariable 
logistic regression to account for their effects to avoid a false positive error. 1, 2 
      Other reasons can impact the p-values as well. In particular, we suspect that the relatively 
small sample size can be a possible explanation. Both the random error and the overall 
variability are generally reduced as the sample size increases, which may enable us to detect 
even relatively small differences between groups. Our sample size provided power to detect 
an OR equal to or greater than 1.83,but was too small to provide a statistically reliable 
estimate of the smaller observed adjusted OR of 1.54.3  
      Additionally, we defined the high out-of-pocket cost burden as the out-of-pocket cost, 
excluding insurance premiums, amounted to 10% or more of the person’s annual income. 
The 10% threshold is set because previous papers used the same rule4, 5. A recent study also 
named it as “underinsurance”, an indicator of the level of patients’ own financial burden. 
Moreover, that study defined another indicator - “high total cost burden”, which means the 
sum of out-of-pocket cost and the insurance premiums amounting to 20% or more of the 
annual income.6 However, there were a lot of missing values in the insurance premiums in 
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MCBS data, so we cannot estimate the relationship between depression and high total cost 
burden. 
      Further research using different data sources is needed. Since depression already proved 
to increase the financial burden for general elderly in previous studies7, 8 and in cancer 
patients in Aim 2 in our study, it is still possible to be associated with high out-of-pocket cost 
burden (underinsurance) and/or high total cost burden.  
Conclusion 
      After adjusting for other covariates, depression was not significantly associated with high 
out-of-pocket cost burden. Further research is needed to explore the topic about depression 
and elderly cancer patients’ financial burden. 
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Table 1. Rates of high out-of-pocket cost burden by patients’ characteristics 
 
 Without Depression With Depression  
Characteristics 
Weighted 
Rates  
95% 
Confidence 
Interval 
Weighted 
Rates 
95% 
Confidence 
Interval 
 
 
P-Value 
Total rates 38.12 
 
(34.5,41.87) 53 
 
(41.72,63.98) 
 
0.023 
Year of cancer diagnosis      
2007-2009 37.07 (31.45-43.05) 50.29 (36.58-63.95) 0.079 
2010-2012 39.16 (33.74-44.86) 55.14 (39.29-70.02) 0.074 
Gender      
Female 40.26 (34-46.84) 49.21 (35.65-62.89) 0.223 
Male 36.64 (31.9-41.65) 56.59 (42.31-69.85) 0.015 
Age      
65-74 37.43 (30.27-45.18) 46.35 (27.77-66.01) 0.415 
75 and over 38.56 (33.77-43.58) 58.83 (47.81-69.02) 0.003 
Race/ethnicity      
White 38.57 (34.66-42.63) 50.73 (39.03-62.35) 0.077 
Other 33.93 (24.58-44.73) 67.23 (33.34-89.33) 0.045 
Marital status      
Married 42.9 (37.97-47.97) 54.07 (38.63-68.77) 0.211 
Other 29.46 (23.5-36.22) 51.25 (36.56-65.73) 0.005 
Educational attainment      
Less than high school 41.68 (33.07-50.84) 50.18 (41.1-75.08) 0.079 
High school 45.27 (38.39-52.34) 67.35 (49.13-81.5) 0.018 
Greater than high school 31.28 (26.03-37.06) 41.49 (25.86-59.05) 0.276 
Poverty status      
LT 200% FPL 34.31 (30.33-38.53) 46.36 (32.18-61.15) 0.141 
GE 200% FPL 50.76 (42.19-59.28) 64.72 (47.53-78.79) 0.157 
Supplemental insurance      
Private insurance with Rx 32.34 (26.36-38.96) 48.03 (32.64-63.8) 0.071 
Public insurance with Rx 34.95 (23.22-48.85) 68.98 (45.61-85.5) 0.013 
Medical Insurance only 42.46 (36.03-49.17) 50.53 (34.02-66.92) 0.419 
Other 51.24 (31.63-70.48) 43.01 (12.39-80.11) 0.703 
Cancer site      
Lung 44.09 (30.26-58.9) 72.4 (49.29-87.63) 0.034 
Breast 41.08 (34.28-48.24) 46.04 (30.67-62.19) 0.567 
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Prostate 34.69 (29.83-39.88) 53.57 (38.36-68.15) 0.027 
Perceived health status      
Excellent/very good/Good 33.77 (29.41-38.41) 37.28 (25.53-50.76) 0.638 
Fair/poor 58.53 (48.72-67.71) 76.95 (62.09-87.19) 0.042 
Functional status limitation      
0 34.31 (30.09-38.79) 47.79 (33.25-62.72) 0.098 
>=1 50.1 (42.83-57.36) 61.78 (45.55-75.74) 0.187 
Number of comorbid health 
conditions     
 
0-1 27.01 (21.11-33.84) 35.65 (17.33-59.42) 0.45 
>1 43.99 (38.89-49.22) 57.34 (45.77-68.16) 0.06 
Smoking Status      
Current 39.78 (24.69-57.09) 49.94 (22.21-77.68) 0.55 
Past 40.14 (34.4-46.17) 50.32 (38.89-67.22) 0.13 
Never 35.02 (28.88-41.71) 53.17 (39.25-66.6) 0.02 
BMI      
Underweight/normal 28.76 (23.17-35.09) 46.69 (30.7-63.39) 0.016 
Overweight 40.1 (34.2-46.31) 50.86 (36.01-65.56) 0.218 
Obese/morbid obese 49.71 (41.14-58.29) 69.24 (43.02-87.03) 0.144 
Metro status      
Metropolitan 34.56 (30.38-39) 51.52 (37.29-65.51) 0.038 
Non-Metropolitan 48.1 (41.51-54.75) 56.85 (41.36-71.1) 0.341 
 
Note: LT, less than; GE, greater than or equal to; FPL, federal poverty level; Rx, prescription 
coverage; BMI, body mass index. 
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Table 2. Univariate regression results 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Odds ratio  
(95% Confidence 
Interval) 
P-value 
Depression (Ref=No)   
 Yes 1.83(1.08-3.09) 0.024 
 
 
66 
 
Table 3. Multivariable logistic regression modeling of depression and high out-of-cost 
burden  
 Odds ratio  
(95% Confidence 
Interval) 
P-value 
Depression (Ref=No)   
 Yes 1.54(0.86-2.74) 0.144 
   
Year of cancer diagnosis 
(Ref=2007-2009) 
  
  2010-2012 1.10(0.77-1.58) 0.587 
   
Gender(Ref=Male)   
  Female 0.88(0.33-2.34) 0.794 
   
Age at diagnosis, years 
(Ref=65-74 years) 
  
  75 and over 1.41 (0.94-2.12) 0.100 
   
Race/ethnicity (Ref= White)   
  Other race 0.75(0.39-1.45) 0.386 
   
Marital status (Ref=Other)   
  Married 2.92(1.83-4.69) 0.000 
   
Educational 
attainment(Ref=Less than 
high school) 
  
  High school 1.55(0.93-2.60) 0.095 
  Greater than high school 0.94(0.94-0.57) 0.79 
   
Poverty Status (Ref=LT 
200% FPL) 
  
  GE to  200% FPL 0.4(0.24-0.67) 0.001 
   
Supplemental 
insurance(Ref= Private 
insurance with Rx) 
  
  Public insurance with Rx 0.86 (0.39-1.88) 0.697 
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Note: LT, less than; GE, greater than or equal to; FPL, federal poverty level; Rx, prescription 
coverage; BMI, body mass index. 
 
 
 
 
 
 
 
  Medical Insurance only 1.43 (1.00-2.05) 0.052 
  Other 1.40 (0.72-2.74) 0.322 
   
Cancer Site(Ref=Lung)   
  Breast 1.03(0.45-2.39) 0.937 
  Prostate 0.60(0.31-1.17) 0.133 
Perceived Health Status(Ref= 
Excellent/very good/Good) 
  
  Fair/Poor 2.69(1.79-4.04) 0.000 
   
Functional status 
limitation(Ref=0) 
  
  At least one 1.28(0.86-1.91) 0.224 
   
Number of comorbid health 
conditions(Ref=0-1) 
  
  >1 1.58(1.06-2.36) 0.024 
   
Smoking Status(Ref=Current)   
 Past 1.03(0.51-2.10) 0.930 
 Never 1.03(0.49-2.16) 0.933 
   
BMI(Ref= 
Underweight/normal) 
  
 Overweight 1.52(1.01-2.29) 0.046 
 Obese/morbid obese 2.03(1.24-3.30) 0.005 
   
Metro 
Status(Ref=Metropolitan) 
  
 Non-Metropolitan 1.41(0.98-2.03) 0.060 
